Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Liabilities (2019 - 2026)

Maxcyte has reported Total Liabilities over the past 7 years, most recently at $31.0 million for Q4 2025.

  • Quarterly Total Liabilities fell 6.63% to $31.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.0 million through Dec 2025, down 6.63% year-over-year, with the annual reading at $31.0 million for FY2025, 6.63% down from the prior year.
  • Total Liabilities was $31.0 million for Q4 2025 at Maxcyte, down from $33.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $36.1 million in Q4 2023 and troughed at -$81.3 million in Q1 2021.
  • The 5-year median for Total Liabilities is $31.3 million (2024), against an average of $24.1 million.
  • Year-over-year, Total Liabilities soared 138.79% in 2021 and then dropped 8.0% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $21.2 million in 2021, then surged by 54.01% to $32.7 million in 2022, then grew by 10.47% to $36.1 million in 2023, then dropped by 8.0% to $33.2 million in 2024, then fell by 6.63% to $31.0 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Total Liabilities are $31.0 million (Q4 2025), $33.2 million (Q3 2025), and $29.0 million (Q2 2025).